Drug Trial Radar · NCT05996523
Phase II Trial of Immunotherapeutic HPV Vaccine PRGN-2009 With Pembrolizumab Before Standard Treatment in Subjects With Newly Diagnosed HPV-Associated Oropharyngeal Cancer
Last checked: Nov 19, 2026Latest source record: Jun 23, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
26
Actual
Start
Nov 7, 2023
Primary completion
May 22, 2025
Study completion Jul 16, 2030
Sponsor
- Lead sponsor
- National Cancer Institute (NCI)NIH
- Sponsor type
- NIH
- First posted
- Aug 18, 2023
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 120 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Background: Cancers in and around the mouth associated with human papilloma virus (HPV) are common. Two treatments (the drug pembrolizumab and the HPV vaccine PRGN-2009) have been shown to work well when used individually against these cancers. Researchers want to find out if they might work better when used together. Objective: To test pembrolizumab combined with PRGN-2009 in people with HPV-positive cancers in and around the mouth. Eligibility: Adults aged 18 and older newly diagnosed with HPV-positive cancers in and around the mouth. Design: Participants will be screened. They will have a physical exam with blood tests. They will have imaging scans. They may need to have a biopsy: A sample of tissue will be taken from the tumor. PRGN-2009 is given as an injection under the skin. Pembrolizumab is given through a tube attached to a needle inserted into a vein in the arm. Participants will have at least 3 clinic visits: At the first, they will receive both the drug and the vaccine; 15 days later, they will receive a second shot of the vaccine. At the third visit, about 1 week after the second, they will have follow-up tests. During these visits, participants will give samples of blood, urine, and saliva. Imaging scans and biopsies will be repeated. They will have tests of their heart function. Participants may opt to return for another follow-up visit about 1 month after their second dose of the vaccine. Participants will have follow-up contacts by phone 3 and 6 months after starting the study. The calls will continue once a year for 5 years.
Conditions
- Oropharyngeal Squamous Cell Carcinoma (SCC)
Interventions
PRGN-2009Biological
PRGN-2009 5x10\^11 viral particles (VP) subcutaneously (SC) approximately two weeks apart
PembrolizumabDrug
Pembrolizumab 200 mg intravenously (IV) concurrently with the first vaccine dose
EKGDiagnostic test
Baseline, completion visit, and safety follow-up visit.
CTDiagnostic test
Screening and baseline (neck and chest), and completion visit (neck).
PET scanDiagnostic test
Screening and baseline (neck and chest).
MRIDiagnostic test
Screening and baseline (neck and chest), and completion visit (neck).
BiopsyProcedure
Baseline and completion visit.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of Participants That Had a 2-fold Increase of Cluster of Differentiation 3 (CD3+) Tumor Infiltrating T Cells in Biopsies Performed Post-treatment Compared to Pre-treatment.Time frame: Pre-Treatment (Baseline) and anytime between Week 4-5 post treatment
Locations
1 site in 1 country. Site status is shown where the registry gives one.
National Institutes of Health Clinical Center
Bethesda, Maryland
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.